Literature DB >> 21912922

Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae.

M Parta1.   

Abstract

The Clinical and Laboratory Standards Institute has recommended that Enterobacteriaceae susceptibility to most cephalosporins and carbapenems be reported according to minimum inhibitory concentration (MIC) alone. We analyzed our record of multi-drug resistant Enterobacteriaceae to assess the impact of these changes. We compared susceptibilities of ceftriaxone-resistant Enterobacteriaceae when using the 2009 and new 2010 MIC standards. Vitek2® (BioMerieux), was used to assess the changes in susceptibility. Klebsiella pneumoniae, Proteus sp., and Escherichia coli were the major species from urine, sputum, blood, and other sterile sites. The new breakpoint for cephalosporins increased resistance in E. coli and P. mirabilis. Many Proteus categorized as resistant by extended-spectrum beta-lactamase (ESBL) detection or inferred resistance have MICs to ceftriaxone ≤ 1 mcg/ml. New carbapenem breakpoints increased resistant Klebsiella pneumoniae and Proteus mirabilis. The increased ceftriaxone resistance from lowering breakpoints was almost balanced by the loss of resistance in ESBL isolates with MICs ≤ 1 mcg/ml. MIC-based susceptibility for multi-drug resistant Enterobacteriaceae increases the number of resistant isolates. Inferring mechanisms of resistance has a disproportionate effect on the susceptibility of Proteus mirabilis to cephalosporins, and the MIC-based standard has an almost equivalent but opposite effect on Proteus mirabilis susceptibility to carbapenems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21912922     DOI: 10.1007/s10096-011-1394-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C E Smith; B S Tillman; A W Howell; R N Longfield; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Inna Chmelnitsky; Azita Leavitt; David Schwartz; Yehuda Carmeli
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Cefepime MIC breakpoint resettlement in gram-negative bacteria.

Authors:  Bum Sik Chin; Won Youl Seo; David L Paterson; Brian A Potoski; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2009-01       Impact factor: 5.191

Review 6.  Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors:  Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

7.  Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto.

Authors:  L F Mataseje; D A Boyd; B M Willey; N Prayitno; N Kreiswirth; A Gelosia; S M Poutanen; D E Low; S G Jenkins; K Katz; M R Mulvey
Journal:  J Antimicrob Chemother       Date:  2011-03-15       Impact factor: 5.790

8.  Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.

Authors:  Peggy C Kohner; Frans J L Robberts; Franklin R Cockerill; Robin Patel
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

9.  Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria.

Authors:  Patrick D Mauldin; Cassandra D Salgado; Ida Solhøj Hansen; Darshana T Durup; John A Bosso
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

10.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae.

Authors:  J P Quinn; D Miyashiro; D Sahm; R Flamm; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.